Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children
Sign Up to like & getrecommendations! Published in 2024 at "Influenza and Other Respiratory Viruses"
DOI: 10.1111/irv.13294
Abstract: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. read more here.
Keywords: respiratory syncytial; impact nirsevimab; estimated impact; nirsevimab incidence ... See more keywords
Impact of Nirsevimab on RSV and Non‐RSV Severe Respiratory Infections in Hospitalized Infants
Sign Up to like & getrecommendations! Published in 2025 at "Influenza and Other Respiratory Viruses"
DOI: 10.1111/irv.70105
Abstract: Nirsevimab, a monoclonal antibody providing passive immunity against RSV infections in infants, was introduced in Spain in October 2023 for children under 6 months and those born during the epidemic season. This study aimed to compare… read more here.
Keywords: respiratory infections; infections hospitalized; impact nirsevimab; hospitalized infants ... See more keywords